In addition, a joint targeting of CXCR1/2, TGF-β1, and PD-L1 using the CXCR1/2 inhibitor SX-682 and bintrafusp alfa also reduces EMT, enhances the infiltration of effector T cells and promotes the blockade of granulocytic myeloid cells in breast and lung cancer mouse models in vivo [151]. This evidence concerns the gene TGFB1 and lung cancer.